Healthcare / BiotechnologyNasdaqCM
$1.07
+0.04 (+3.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-1.8M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.9%
↓Gross Margin
N/A
•Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.4M · FCF $-1.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $431378.00 | $1.3M |
| Net Income | $-1.4M | $-1.4M | $-4.3M | $-2.8M | $-9.8M |
| EBITDA | $-1.8M | $-1.8M | $-2.7M | $-9.2M | $-15.6M |
| EPS | — | — | — | -0.62 | -2.75 |
| Gross Margin | — | — | — | 2.4% | 6.2% |
| Operating Margin | — | — | — | -2457.5% | -1325.2% |
| Net Margin | — | — | — | -654.8% | -756.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.16 | 0.13 | 0.44 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.8M | $-1.8M | $-1.2M | $-7.7M | $-12.5M |
| Returns | |||||
| ROE | -5.9% | -5.9% | -20.2% | -11.4% | -62.4% |
| Valuation | |||||
| P/B | 0.38 | 0.38 | 0.57 | 0.41 | 1.25 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -66.7% | — |
| EPS Growth | — | — | — | 77.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.3%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+16.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.